October 8, 2021 08:33 AM EDT
Bioregnum

Care about R&D strate­gies? Have we got a sum­mit for you

If there’s one un­der­ly­ing les­son I’ve learned watch­ing bio­phar­ma in ac­tion over the past 20 years or so, it’s that no R&D or­ga­ni­za­tion can rest …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

A service from the Financial Times